Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3152MR)

This product GTTS-WQ3152MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3152MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10776MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ12119MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ12198MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ6899MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ10401MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ7837MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ6537MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ7100MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW